Division of Pediatrics, Department of Pediatric Gastroenterology, Wilhelmina Children's Hospital, Utrecht University, Utrecht, The Netherlands; Regenerative Medicine Center, Utrecht University, Utrecht, The Netherlands.
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Gastroenterology. 2018 Jul;155(1):130-143.e15. doi: 10.1053/j.gastro.2018.03.040. Epub 2018 Mar 29.
BACKGROUND & AIMS: Congenital diarrheal disorders are rare inherited intestinal disorders characterized by intractable, sometimes life-threatening, diarrhea and nutrient malabsorption; some have been associated with mutations in diacylglycerol-acyltransferase 1 (DGAT1), which catalyzes formation of triacylglycerol from diacylglycerol and acyl-CoA. We investigated the mechanisms by which DGAT1 deficiency contributes to intestinal failure using patient-derived organoids.
We collected blood samples from 10 patients, from 6 unrelated pedigrees, who presented with early-onset severe diarrhea and/or vomiting, hypoalbuminemia, and/or (fatal) protein-losing enteropathy with intestinal failure; we performed next-generation sequencing analysis of DNA from 8 patients. Organoids were generated from duodenal biopsies from 3 patients and 3 healthy individuals (controls). Caco-2 cells and patient-derived dermal fibroblasts were transfected or transduced with vectors that express full-length or mutant forms of DGAT1 or full-length DGAT2. We performed CRISPR/Cas9-guided disruption of DGAT1 in control intestinal organoids. Cells and organoids were analyzed by immunoblot, immunofluorescence, flow cytometry, chromatography, quantitative real-time polymerase chain reaction, and for the activity of caspases 3 and 7.
In the 10 patients, we identified 5 bi-allelic loss-of-function mutations in DGAT1. In patient-derived fibroblasts and organoids, the mutations reduced expression of DGAT1 protein and altered triacylglycerol metabolism, resulting in decreased lipid droplet formation after oleic acid addition. Expression of full-length DGAT2 in patient-derived fibroblasts restored formation of lipid droplets. Organoids derived from patients with DGAT1 mutations were more susceptible to lipid-induced cell death than control organoids.
We identified a large cohort of patients with congenital diarrheal disorders with mutations in DGAT1 that reduced expression of its product; dermal fibroblasts and intestinal organoids derived from these patients had altered lipid metabolism and were susceptible to lipid-induced cell death. Expression of full-length wildtype DGAT1 or DGAT2 restored normal lipid metabolism in these cells. These findings indicate the importance of DGAT1 in fat metabolism and lipotoxicity in the intestinal epithelium. A fat-free diet might serve as the first line of therapy for patients with reduced DGAT1 expression. It is important to identify genetic variants associated with congenital diarrheal disorders for proper diagnosis and selection of treatment strategies.
先天性腹泻性疾病是罕见的遗传性肠道疾病,其特征为顽固性、有时危及生命的腹泻和营养吸收不良;其中一些与二酰基甘油酰基转移酶 1(DGAT1)的突变有关,该酶催化二酰基甘油和酰基辅酶 A 形成三酰基甘油。我们使用患者来源的类器官研究了 DGAT1 缺乏导致肠道衰竭的机制。
我们从 6 个无关家系的 10 名表现为早发性严重腹泻和/或呕吐、低白蛋白血症和/或(致命性)蛋白丢失性肠病伴肠道衰竭的患者中采集了血液样本;对 8 名患者的 DNA 进行了下一代测序分析。从 3 名患者和 3 名健康个体(对照)的十二指肠活检中生成类器官。用表达全长或突变形式的 DGAT1 或全长 DGAT2 的载体转染或转导 Caco-2 细胞和患者来源的皮肤成纤维细胞。我们用 CRISPR/Cas9 引导的方法对对照肠道类器官中的 DGAT1 进行了破坏。通过免疫印迹、免疫荧光、流式细胞术、色谱、定量实时聚合酶链反应以及半胱天冬酶 3 和 7 的活性分析细胞和类器官。
在 10 名患者中,我们发现了 5 个双等位基因失活功能突变的 DGAT1。在患者来源的成纤维细胞和类器官中,这些突变降低了 DGAT1 蛋白的表达,并改变了三酰基甘油代谢,导致油酸添加后脂滴形成减少。全长 DGAT2 在患者来源的成纤维细胞中的表达恢复了脂滴的形成。与对照类器官相比,源自 DGAT1 突变患者的类器官对脂类诱导的细胞死亡更为敏感。
我们鉴定了一大群患有先天性腹泻疾病的患者,其 DGAT1 突变降低了其产物的表达;这些患者的皮肤成纤维细胞和肠道类器官改变了脂质代谢,并对脂类诱导的细胞死亡敏感。全长野生型 DGAT1 或 DGAT2 的表达恢复了这些细胞的正常脂质代谢。这些发现表明 DGAT1 在肠道上皮细胞的脂肪代谢和脂毒性中具有重要作用。无脂肪饮食可能是治疗 DGAT1 表达降低患者的一线治疗方法。确定与先天性腹泻性疾病相关的遗传变异对于正确诊断和选择治疗策略很重要。